Wir sind mit live! Mehr erfahren

Travere Therapeutics

TVTX

Börsenwert 4,68 Mrd. $

49,60 USD

-3,19

6,04 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

49,60

0,00

0 %

1 Tag

-6,04 %

5 Tage

-4,14 %

1 Monat

-21,87 %

3 Monate

-10,27 %

6 Monate

25,44 %

Seit Jahresbeginn

25,51 %

1 Jahr

80,3 %

5 Jahre

103,78 %

10 Jahre

139,38 %

Profil: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Mitarbeiter: 497

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 22,7 %

Neutral 72,7 %

Negativ 4,5 %

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 142,580 shares of its common stock. These induceme.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)."The final SPARTAN analysis provides a compelling picture of what's possible whe.

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain me.

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics Announces Planned Chief Executive Officer Transition

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and.

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.About Travere TherapeuticsAt Travere Therapeutics, we are in rare.

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted a.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors Business Daily

Travere Therapeutics' Outlook Brightens As Turnaround Looms

Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.

Travere Therapeutics' Outlook Brightens As Turnaround Looms

Investors Business Daily

Three Biotech Stocks Stick Out With Their Stellar Charts

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Three Biotech Stocks Stick Out With Their Stellar Charts

Travere Therapeutics: Valuation Suggests A Buy

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.

Travere Therapeutics: Valuation Suggests A Buy

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt